Keros Therapeutics, Inc.
KROS
Positions held
Your positionsKROS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $230.79M | Enterprise value | -$11.09M | Trailing P/E | — | Forward P/E | -1.76 |
| PEG | — | Price / book | 0.88 | Beta | 1.12 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -6.6% |
| Profit margin | 0.0% | ROE | -17.2% | ROA | -11.8% | Debt / equity | 0.06 |
| Current ratio | 21.96 | Free cash flow | -$27.17M | Analyst recommendation | buy | Mean target | $19.83 |
| 52w high | $22.55 | 52w low | $9.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.4M | $0.4M | $14.3M | $18.2M |
| Op margin | — | -7051.0% | -7602.6% | -107.9% | -219.2% |
| Net income | -$28.7M | -$23.7M | -$23.5M | -$7.3M | -$30.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$30.9M | -$25.9M | -$29.3M | -$15.4M | -$39.8M |
- Revenue -100% vs prior quarter ($0 vs $0.4M).
- Operating margin expanded to -7051%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $244M | $3.5M | $0.2M | $0.0M | — |
| Op margin | 27.7% | -5904.1% | -110954.3% | — | — |
| Net income | $87.0M | -$187M | -$153M | -$105M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $67.6M | -$210M | -$168M | -$108M | — |
Headlines — watch
• [WARN · fundamentals] KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
News
2026-10-07 · Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
2026-09-29 · Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
2026-09-29 · KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
2026-09-29 · Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
2026-09-28 · Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
2026-09-08 · Keros Therapeutics Approves $5 Million Share Buyback
2026-09-08 · Keros Therapeutics Announces $5 Million Share Repurchase Authorization
2026-09-02 · Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
2026-08-24 · KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
2026-08-24 · Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
2026-08-04 · KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Price (daily)
Full chart · RSI · MACD · patterns